The Boehringer Ingelheim and Lilly Alliance Supports ACC COVID-19 Response Initiative

September 17, 2020

The American College of Cardiology’s (ACC) ongoing COVID-19 response initiative is welcoming support from the Boehringer Ingelheim and Eli Lilly and Company Alliance to continue providing real-time clinical guidance on COVID-19. The comprehensive initiative includes a robust set of activities and events implemented by ACC to help cardiologists address critical patient needs and continue to deliver high-quality care.

People with existing cardiovascular disease are at high risk of lung damage and cardiovascular complications if they contract COVID-19. This is further complicated by an increased risk of developing co-morbid conditions associated with heart disease. As the pandemic progresses, many clinicians are looking for real-time guidance on managing care for these vulnerable patients, while minimizing risk to themselves and the entire cardiovascular care team.

The ACC has increasingly focused its COVID-19 response initiative on four broad areas of critical need, including key clinical/scientific guidance, optimizing cardiovascular care and operational considerations, clinician wellness, and disparities in care. This initiative, anchored by ACC’s COVID-19 hub, provides a platform for providing education and resources around these areas that clinicians can immediately put into practice as the pandemic evolves.

“The ACC is committed to transforming cardiovascular care and improving heart health, and today, that can’t be accomplished without addressing the impact the pandemic has had on our patients,” said ACC President Athena Poppas, MD, FACC. “Through this initiative, we are supporting members to answer pressing clinical questions, develop care delivery models and update the science for the health of our practices and our patients.”

Highlights of the programs and resources offered in ACC’s COVID-19 response initiative include:

  • The Summer COVID-19 Education Series – A free weekly virtual meeting providing the health care community with actionable insights and solutions to address key clinical and operational concerns.
  • Quick Tips for Fast Thinking – A video library featuring ACC thought leaders providing structured reviews of emerging science, perspectives from the frontline, and guidance on non-clinical issues and sharing best practices.
  • “Cardiology care teams need support in navigating the unique challenges brought on by COVID-19 to ensure that this high-risk patient community continues to receive the best possible care, guided by the latest science and recommendations,” said Mohamed Eid, MD, MPH, MHA, vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc. “The Boehringer Ingelheim and Lilly Alliance is proud to partner with the ACC to deliver real-time education to ensure the continuity of high-quality care to people with cardiovascular disease.”

    To access the ACC’s comprehensive tools and resources for clinicians and patients, visit the ACC’s COVID-19 Hub at www.acc.org/COVID19.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”